{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:41:13Z","timestamp":1791481273765,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.trre.2022.100729","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T13:20:16Z","timestamp":1667568016000},"page":"100729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review"],"prefix":"10.1016","volume":"37","author":[{"given":"Yolanda","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merisa","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Battistella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2022.100729_bb0005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.7861\/clinmed.2019-0195","article-title":"Post-transplant diabetes mellitus","volume":"19","author":"Chowdhury","year":"2019","journal-title":"Clin Med"},{"key":"10.1016\/j.trre.2022.100729_bb0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2022.100729_bb0015","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2022.100729_bb0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","article-title":"Pharmacologic glycemic management of Type 2 diabetes in adults: 2020 update diabetes Canada clinical practice guidelines expert committee","volume":"44","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2020","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.trre.2022.100729_bb0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.trre.2022.100729_bb0030","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2022.100729_bb0035","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","article-title":"Use of Empagliflozin in recipients of kidney transplant: a report of 8 cases","volume":"51","author":"Attallah","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2022.100729_bb0040","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0045","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0050","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0060","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.trre.2022.100729_bb0070","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","journal-title":"Kidney Int [Internet]"},{"key":"10.1016\/j.trre.2022.100729_bb0075","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/tri.13883","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation","volume":"34","author":"Ertuglu","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2022.100729_bb0080","article-title":"Review of newer antidiabetic agents for diabetes management in kidney transplant recipients","volume":"1\u201313","author":"Anderson","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.trre.2022.100729_bb0085","first-page":"1","article-title":"Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis","volume":"8","author":"Chewcharat","year":"2020","journal-title":"Med Sci"},{"key":"10.1016\/j.trre.2022.100729_bb0090","first-page":"CD009966","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","volume":"8","author":"Lo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2022.100729_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108604","article-title":"Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: a systematic review and meta-analysis","volume":"172","author":"Oikonomaki","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.trre.2022.100729_bb0100","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0105","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0110","author":"Veritas Health Innovation"},{"key":"10.1016\/j.trre.2022.100729_bb0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0120","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.trre.2022.100729_bb0125","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2022.100729_bb0130","author":"Cochrane Methods Bias"},{"key":"10.1016\/j.trre.2022.100729_bb0135","author":"Corporation M"},{"key":"10.1016\/j.trre.2022.100729_bb0140","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.trre.2022.100729_bb0145","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation."},{"key":"10.1016\/j.trre.2022.100729_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-022-02793-9","article-title":"Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: five Japanese cases","volume":"23","author":"Miyazaki","year":"2022","journal-title":"BMC Nephrology"},{"key":"10.1016\/j.trre.2022.100729_bb0155","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2022.100729_bb0160","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.trre.2022.100729_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.185","article-title":"Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients","volume":"4","author":"Song","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.trre.2022.100729_bb0170","article-title":"Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients","volume":"5","author":"Cehic","year":"2019","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2022.100729_bb0175","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.healun.2021.02.012","article-title":"Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of excellence","volume":"40","author":"Sammour","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2022.100729_bb0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2019.11.007","article-title":"Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients","volume":"52","author":"AlKindi","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2022.100729_bb0185","first-page":"16","article-title":"Use of SGLT2 inhibitors in diabetic renal transplant recipients: a mixed method exploratory exercise","volume":"24","author":"Beshyah","year":"2018","journal-title":"Int J Diabetes Metab"},{"key":"10.1016\/j.trre.2022.100729_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000507259","article-title":"Fulminant emphysematous pyelonephritis by Candida glabrata in a kidney allograft","volume":"144","author":"Cases-Corona","year":"2020","journal-title":"Nephron."},{"key":"10.1016\/j.trre.2022.100729_bb0195","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/XCE.0000000000000246","article-title":"Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review","volume":"10","author":"Gul","year":"2021","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.trre.2022.100729_bb0200","doi-asserted-by":"crossref","first-page":"E772","DOI":"10.1097\/TXD.0000000000001228","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with pretransplant type 2 diabetes mellitus: a retrospective, single-center, inverse probability of treatment weighting analysis of 85 transplant patients","volume":"7","author":"Hisadome","year":"2021","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2022.100729_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.14718","article-title":"Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation","volume":"36","author":"Lemke","year":"2022","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2022.100729_bb0210","first-page":"1","article-title":"Type 2 diabetes focused update: SGLT2 inhibitors and GLP1 agonists [internet]","author":"B.C. Provincial Academic Detailing Service","year":"2022","journal-title":"Provin Acad Detail"},{"key":"10.1016\/j.trre.2022.100729_bb0215","author":"U.S. National Library of Medicine"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X22000520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X22000520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:06:38Z","timestamp":1760630798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X22000520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0955470X22000520"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2022.100729","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2022.100729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100729"}}